US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...

Eli Lilly launches diabetes and obesity drug Mounjaro in India, offering innovative treatment for metabolic health management ...

Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

They matched 33,220 patients taking semaglutide, liraglutide (Saxenda), exenatide (Byetta, Bydureon), dulaglutide (Trulicity), tirzepatide (Zepbound), and lixisenatide (no longer available in the ...

It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent ...

New weight loss drugs like Ozempic and Wegovy help suppress appetite, leading to significant weight loss, but they come with ...

Additionally, GLP-1 agonists such as dulaglutide, semaglutide and liraglutide have been shown to provide cardiovascular benefits. Doctors may also recommend these GLP-1 agonists to reduce the risk ...

In recent years, there have been more developments in the area of diabetes management, with the emergence of metformin and more recently semaglutide and dulaglutide. However, despite these ...

Similarly, GLP-1 receptor agonists like Victoza (liraglutide), Ozempic (semaglutide), and Trulicity (dulaglutide) can also aid in weight loss while lowering the risk of cardiovascular disease. With ...

Tirzepatide and lifestyle modification generated 48,649 life-years gained per 100,000 eligible individuals, and semaglutide and lifestyle modification generated 35,634 life-years gained per ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...